Ascendis Pharma A/S (NASDAQ:ASND) Lowered to “Sell” Rating by StockNews.com

Ascendis Pharma A/S (NASDAQ:ASND) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued on Tuesday.

Several other research firms also recently weighed in on ASND. TD Cowen raised their price target on Ascendis Pharma A/S from $157.00 to $160.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. Oppenheimer reiterated an “outperform” rating and set a $190.00 price objective (up from $180.00) on shares of Ascendis Pharma A/S in a research note on Tuesday, September 17th. JPMorgan Chase & Co. reduced their target price on shares of Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating for the company in a research note on Wednesday, October 23rd. Citigroup boosted their target price on shares of Ascendis Pharma A/S from $178.00 to $207.00 and gave the stock a “buy” rating in a report on Tuesday, September 17th. Finally, Wells Fargo & Company raised their price objective on Ascendis Pharma A/S from $264.00 to $289.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 17th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $195.92.

Ascendis Pharma A/S Trading Down 0.6 %

Shares of ASND stock traded down $0.73 on Tuesday, reaching $127.67. 417,745 shares of the stock were exchanged, compared to its average volume of 442,516. The business’s 50 day moving average price is $131.91 and its 200 day moving average price is $132.90. The company has a market capitalization of $7.74 billion, a price-to-earnings ratio of -13.71 and a beta of 0.66. Ascendis Pharma A/S has a twelve month low of $86.54 and a twelve month high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings data on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The firm had revenue of $38.75 million during the quarter, compared to analyst estimates of $94.74 million. Equities research analysts forecast that Ascendis Pharma A/S will post -7.35 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Signaturefd LLC increased its position in shares of Ascendis Pharma A/S by 13.2% during the 3rd quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 80 shares during the last quarter. Profund Advisors LLC boosted its holdings in shares of Ascendis Pharma A/S by 3.0% during the second quarter. Profund Advisors LLC now owns 2,919 shares of the biotechnology company’s stock worth $398,000 after acquiring an additional 85 shares during the period. Rhumbline Advisers increased its stake in shares of Ascendis Pharma A/S by 10.3% during the second quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock worth $209,000 after purchasing an additional 143 shares during the period. Thrivent Financial for Lutherans lifted its holdings in Ascendis Pharma A/S by 0.3% during the 3rd quarter. Thrivent Financial for Lutherans now owns 78,473 shares of the biotechnology company’s stock worth $11,717,000 after purchasing an additional 228 shares during the last quarter. Finally, Avior Wealth Management LLC grew its stake in shares of Ascendis Pharma A/S by 3.0% in the third quarter. Avior Wealth Management LLC now owns 8,212 shares of the biotechnology company’s stock valued at $1,226,000 after acquiring an additional 240 shares in the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.